Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Soleno Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases, notably Prader-Willi syndrome (PWS). Its lead product, DCCR, aims to reduce hyperphagia and behavioral symptoms by targeting physiological pathways involving appetite and fat regulation. The company advances its therapies through clinical trials, regulatory approvals, and targeted commercialization, addressing significant unmet medical needs in the rare disease market.
This description was generated via AI from an annual report. Updated about 1 year ago.